OCUS BIOSCIENCES

Locus Biosciences is a private clinical-stage biotechnology company developing precision engineered bacteriophage therapies for bacterial infections and microbiome-related diseases. Its lead program, LBP-EC01, is in a registration-enabling Phase 2/3 ELIMINATE study for acute uncomplicated urinary tract infections caused by multidrug-resistant Escherichia coli. The company combines bacteriophage synthetic biology, CRISPR-Cas3 payload engineering, artificial intelligence, robotics, and bioinformatics in its LOCUS platform to design pathogen-specific antibacterial medicines. Beyond E. coli, Locus is advancing programs against Pseudomonas aeruginosa, Staphylococcus aureus, and Klebsiella pneumoniae, and is also exploring immunology applications such as inflammatory bowel disease. The company has internal cGMP viral vector manufacturing capabilities and has partnered with organizations including BARDA, NIH/NIAID, and Viatris.